Developing a managed care-pharmaceutical research partnership.
Increasingly, MCOs ask pharmaceutical companies for evidence of a new product's cost effectiveness before adding it to the formulary. This article examines a research partnership between a pharmaceutical company and 14 MCOs to assess the cost effectiveness of a new medication for osteoarthritis. The research partnership, a study protocol, and research activities are discussed.
Lewis
B E
BE
Focus Managed Research, Inc., Philadelphia, PA, USA.
Kimmelheim
R
R
Gondek
K
K
Lister
B
B
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D003299:Cooperative Behavior; D003362:Cost-Benefit Analysis; D016861:Cyclooxygenase Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D004345:Drug Industry / Q000458:organization & administration*; D005569:Formularies as Topic; D006801:Humans; D008329:Managed Care Programs / Q000458:organization & administration*; D000077239:Meloxicam; D010003:Osteoarthritis / Q000188:drug therapy; D012106:Research / Q000458:organization & administration; D013843:Thiazines / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D013844:Thiazoles / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D014481:United States
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016861:Cyclooxygenase Inhibitors; D013843:Thiazines; D013844:Thiazoles; D000077239:Meloxicam